MONOGRAM Technologies
MONOGRAM Technologies is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at MONOGRAM Technologies.
MONOGRAM Technologies is a company.
Key people at MONOGRAM Technologies.
Monogram Technologies is a medical device company developing a surgical robot and personalized orthopedic implants for reconstructive joint replacement procedures, primarily total knee arthroplasty (TKA).[1][2] It serves orthopedic surgeons and patients by addressing inaccuracies in traditional implant placement through robot-enabled, patient-optimized surgery that integrates machine vision, augmented reality, and AI, aiming to simplify techniques like kinematic alignment, reduce complications, and lower costs.[1][2] The company, with 27 employees and headquartered in Austin, Texas, is pre-commercialization, focusing on FDA 510(k) clearance for its first-generation mBôs™ TKA System while advancing a second-generation version; it trades publicly as MGRM on NASDAQ after raising over $40 million in funding rounds.[1][3]
Founded in 2015 (with some sources noting 2016), Monogram Technologies—formerly Monogram Orthopaedics, Inc., until its May 2024 name change—emerged from a philosophy that technology advances could transform reconstructive joint procedures.[1][2] Key figures include Founder and Chief Medical Officer Dr. Douglas Unis, an orthopedic expert, alongside CEO and Chairman Benjamin Sexson (C.F.A.), CFO Noel Knape (CPA, M.B.A.), and CTO Dr. Kamran Shamaei (Ph.D.).[1] Early traction built through convertible note rounds ($1.032M and $1.148M), a $21.8M Series B, and investments totaling $4.5M and $17.2M, culminating in its public listing; pivotal moments include UCLA studies showing seven times greater stability in hip replacements and submissions for FDA clearance.[2][3][4]
Monogram rides the wave of robotic surgery and personalized medicine in orthopedics, where over 50 years of stagnant joint reconstruction tech meets rising procedure volumes for knees and hips.[2][4] Timing aligns with FDA clearance pathways and AI/AR integration, amplified by market forces like aging populations and demands for precision to cut failures (e.g., enabling more surgeons for complex alignments).[1][2] It influences the ecosystem by pioneering CT-based robotic prep, potentially lowering costs and complications, while gaining first-to-market edge in a competitive sector; media highlights include Newsweek, Fast Company, and Inc. recognition for 3D-printed personalization and navigated robotics.[4]
Monogram is poised for FDA clearance milestones in 2025-2026, enabling phased launches of its TKA robotic system and implants, with expansion to hips leveraging UCLA-validated stability gains.[2][3][4] Trends like AI-driven personalization and robotic adoption will accelerate growth, evolving its influence from innovator to ecosystem shaper in a high-volume market. As it transitions from development to revenue, expect scaled impact on orthopedic outcomes, mirroring its funding trajectory toward broader surgeon adoption.
Key people at MONOGRAM Technologies.